12:25pm ET
Investing
Meet the Preliminary 2020 Dogs of the Dow
One theme that investors love in good times and in bad is dividend investing. One strategy that has been around for years is known as the Dogs of the Dow.
JNJ Coverage Page 45
10:40am ET
Health and Healthcare
Why These 3 Biotechs More Than Doubled on Monday
Monday was a breakout day for a few biotech companies. Some made absolutely massive runs, practically doubling and then some. The biotechnology sector is pushing near all-time highs, and a few of…
8:55am ET
Investing
Top Analyst Upgrades and Downgrades: Amarin, Baker Hughes, Canopy Growth, Home Depot, Intelsat, J&J, Replimune, Schlumberger, Transocean and More
Wednesday's top analyst upgrades, downgrades and initiations include Amarin, Baker Hughes, Canopy Growth, Home Depot, Intelsat, Johnson & Johnson, Replimune, Schlumberger and Transocean.
10:50am ET
Investing
How Dow 28,000 Can Rapidly Become Dow 30,000 and Even Higher in 2020
Despite the never-ending election cycle, there actually is a clear path for the Dow to hit 30,000 as soon as early 2020, if only a few things come to fruition. There does…
11:20am ET
Investing
As the Dow Hits All-Time High, Over Half of Dow Stocks Keep Disappointing Investors
With markets at all-time highs, it's important to consider the winners and losers. In this case, many stocks in the Dow are still holding the index back from even stronger gains.
6:50am ET
Investing
Why Goldman Sachs Enhanced Income Strategy May Be Perfect for 2020
Goldman Sachs may have the best strategy for investors for 2020. Here are five stocks that look like great ideas now for investors looking to mold such a plan.
5:12pm ET
Companies and Brands
J&J Gets $10 Billion Gift as Lab Results Show No Asbestos in Baby Powder
Johnson & Johnson has found itself involved in more controversy than the company would prefer to see. But it seems that not even bad news lasts forever.
Jon C. Ogg 6:45am ET
Health and Healthcare
How Biotech and Big Pharma Have Upside Heading Into Earnings
Credit Suisse and Merrill Lynch made calls in the biotech and pharmaceutical space last week, ahead of coming earnings reports.
8:45am ET
Investing
Top Analyst Upgrades and Downgrades: Adobe, Alibaba, Amazon, AT&T, Comcast, Delphi, DocuSign, J&J, JPMorgan, T-Mobile, Verizon, Wells Fargo and More
Wednesday's top analyst upgrades, downgrades and initiations included Adobe, Alibaba, Amazon.com, AT&T, Comcast, Delphi Technologies, DocuSign, Johnson & Johnson, JPMorgan, T-Mobile, Verizon Communications and Wells Fargo.
10:29am ET
Health and Healthcare
Johnson & Johnson Offers a Strong Start to Earnings Season
Johnson & Johnson reported better than expected quarterly results before the markets opened on Tuesday.
Chris Lange 12:10pm ET
Health and Healthcare
What to Expect When Johnson & Johnson Reports Tuesday
Johnson & Johnson is scheduled to report its most recent quarterly results before the markets open on Tuesday, and analysts' expectations are mild overall.
Chris Lange 6:50am ET
Investing
Coca-Cola, Goldman Sachs, IBM, Johnson & Johnson and More Dow Stocks Reporting This Week
Seven of the 30 Dow Jones industrial average components are scheduled to report their latest quarterly reports this week.
8:50am ET
Investing
Top Analyst Upgrades and Downgrades: Apple, Canopy Growth, CrowdStrike, Delta, J&J, Rio Tinto, Roku, Square, Tilray, Twilio and More
Friday's top analyst upgrades, downgrades and initiations included Apple, Canopy Growth, CrowdStrike, Delta Air Lines, Johnson & Johnson, Rio Tinto, Roku, Square, Tilray and Twilio.
12:25pm ET
Health and Healthcare
Johnson & Johnson Has a Lot on Its Hands After $8 Billion Court Ruling
Johnson & Johnson shares dropped on Wednesday following the announcement that a jury has awarded $8 billion in damages to a man accusing the drugmaker of failing to warn about the side…
Chris Lange 10:50am ET
Health and Healthcare
Johnson & Johnson May Have Just Dodged a Big Opioid Bullet
One analyst issued a fairly bullish report in response to Johnson & Johnson's announcement of a $10 million settlement with two Ohio counties ahead of an upcoming opioid trial.
Chris Lange